NARCOLEPSY · White paper
Narcolepsy Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About narcolepsy — and why its trials are hard
Narcolepsy is a chronic neurological disorder of sleep-wake regulation marked by excessive daytime sleepiness, sleep paralysis, hypnagogic hallucinations, disrupted nocturnal sleep, and, in type 1, cataplexy. Type 1 narcolepsy is characterized by loss of hypocretin (orexin) signaling, with CSF hypocretin-1 below 110 pg/mL and a strong HLA-DQB1*06:02 association, supporting an autoimmune mechanism; type 2 lacks cataplexy and has normal hypocretin. It affects roughly 25-50 per 100,000 people, often beginning in adolescence with substantial diagnostic delay. Approved therapies target the two symptom clusters: wake-promoting agents (modafinil, solriamfetol) for daytime sleepiness, and sodium oxybate (and low-sodium oxybate, Xywav) and pitolisant for both sleepiness and cataplexy. Trials rely on objective (Maintenance of Wakefulness Test) and subjective (Epworth Sleepiness Scale) measures plus cataplexy diaries, and are hampered by high placebo response, symptom variability across NT1/NT2, and safety concerns. Orexin-agonist programs such as TAK-994 have been halted for hepatotoxicity, underscoring the difficulty of drugging the hypocretin pathway.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Modafinil (Provigil) | 1998 | Excessive daytime sleepiness in narcolepsy (wake-promoting agent) | Pivotal narcolepsy MWT/CGI-C trials | Maintenance of Wakefulness Test and Clinical Global Impression of Change | Significant improvement in staying awake on MWT vs placebo (p<0.001); nighttime sleep unaffected |
| Sodium oxybate (Xyrem) | 2002 | Cataplexy and excessive daytime sleepiness in narcolepsy (CIII; GABA-B agonist, REMS) | Pivotal trials (e.g., NCT00049803) | Cataplexy attack frequency and ESS | Median cataplexy reduction -16 at 9 g vs -4 placebo; ESS -5.0 (9 g) vs -0.5 placebo (p<0.001) |
| Solriamfetol (Sunosi) | 2019 | Excessive daytime sleepiness in narcolepsy and OSA (dopamine-norepinephrine reuptake inhibitor) | TONES program (e.g., NCT02348593) | MWT and ESS | 150 mg increased MWT by ~7.7 min and decreased ESS by ~3.8 points vs placebo (p<0.05) |
| Pitolisant (Wakix) | 2019 | Excessive daytime sleepiness and cataplexy in narcolepsy (histamine H3 receptor antagonist/inverse agonist; non-scheduled) | HARMONY trials (e.g., NCT01800045) | Epworth Sleepiness Scale | Placebo-subtracted ESS difference ~ -3.1 (Study 1); no significant weight or cardiovascular risk |
| Low-sodium oxybate (Xywav) | 2020 | Cataplexy and EDS in narcolepsy (2020) and idiopathic hypersomnia (2021); ~92% lower sodium than Xyrem | Randomized withdrawal study | Weekly cataplexy attacks and ESS | Significant worsening of cataplexy and ESS on placebo vs maintained control on Xywav (p<0.0001) |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in narcolepsy development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| TAK-994 — NCT04820842 (oral orexin receptor agonist) | Takeda halted trials in 2021 | Hepatotoxicity safety signal in Phase 2, prompting reassessment of oral orexin agonists |
| JNJ-17216498 — Early-phase studies | Discontinued | Lack of efficacy and safety concerns |
| Mazindol ER — AMAZE program | Delayed development (not approved) | Regulatory and capital constraints delaying Phase 3 despite Phase 2 efficacy signals |
Choosing the right endpoint
Primary endpoints that matter in narcolepsy trials
- Excessive daytime sleepiness (ESS) — Subjective Epworth Sleepiness Scale; high variability and reporting bias
- Maintenance of Wakefulness Test (MWT) — Objective measure of ability to stay awake; environment-sensitive
- Cataplexy episode frequency — Primary endpoint for anti-cataplexy agents; captured via electronic diaries to reduce recall bias
- Clinical Global Impression of Change (CGI-C) — Clinician-rated overall improvement, often a co-primary/secondary
- Quality of life / functional outcomes (FOSQ, PGI-C) — Secondary endpoints capturing broader daily-function impact
How iNGENū runs narcolepsy trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
The full white paper: approved-product analyses, pivotal endpoints and trial-design strategy. Open-access · no sign-in.
Frequently asked questions
Narcolepsy clinical trials — FAQs
How does narcolepsy type 1 differ from type 2?
Which drugs treat cataplexy versus daytime sleepiness?
Why have orexin agonists like TAK-994 struggled?
Ready to discuss your narcolepsy trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal